# Convergence for Individualizing TReatment Using Statistical approaches (CITRUS)

Max Welz<sup>1,2</sup> Kevin ten Haaf<sup>2</sup> Andreas Alfons<sup>1</sup>

<sup>1</sup>Erasmus University Rotterdam, Dept. of Econometrics

<sup>2</sup>Erasmus Medical Center, Dept. of Public Health

October 21, 2021

TI PhD Seminar



Ezafus

#### Outline

Introduction

2 Data Generation: Considered Scenarios

3 Estimation: Considered Methods



# Background

# CITRUS = Convergence for Individualizing TReatment Using Statistical approaches

- Project of the Econometric Institute and Erasmus Medical Center;
- Part of the Convergence Alliance between EUR, EMC, TU Delft;
- Fully funded by an *Open Mind Call* grant (awarded: 08/2021).



Welz, ten Haaf, Alfons CITRUS October 21, 2021 3/13

Evidence-based medicine: the "conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients" (Sackett et al., 1996).

- → Identify heterogeneous treatment effects (HTE)!
- → Methods from modern causal inference?
- → CITRUS: Which methods are most eligible for medical data?
- → Simulate common characteristics of medical data.



Welz, ten Haaf, Alfons CITRUS October 21, 2021 4 / 13

In a perfect world, we'd have...

- Many observations:  $n \to \infty$ ;
- Perfect information on relevant covariates (unconfoundedness);
- I.I.D. data from randomized experiment;
- Continuous data.

BUT: The world is **not** perfect (especially in medicine...)





Frank Harrell @f2harrell

Note to #Statistics paper authors: If you have the word "asymptotic" in your title or abstract, the probability that I'll read the paper is reduced by a factor of 4. I'm only interested in real-world performance of analytical methods. @vandy\_biostat

5:55 PM · Sep 29, 2021 · TweetDeck



6/13

Welz, ten Haaf, Alfons CITRUS October 21, 2021

In medical data, we typically have...

- Very finite sample sizes ( $n \ge 500$  is rare);
- Noisy to incomplete representation of relevant covariates;
- Non-identically distributed samples;
- Improper randomization (sometimes...);
- Non-continuous data (e.g. categorical).

#### CITRUS research question:

 To what extent does this affect the performance of each HTE estimation method?



7 / 13

#### Outline

Introduction

2 Data Generation: Considered Scenarios

3 Estimation: Considered Methods



October 21, 2021

## Setup

Let there be n independent observations ( $\mathbf{X}_i, Y_i, W_i$ ).

- **X**<sub>i</sub> is *p*-dimensional covariate vector;
- $Y_i$  is outcome variable. Binary mortality indicator here:  $Y_i = 1$  if i dies.
- $W_i$  is binary treatment assignment variable:  $W_i = 1$  if i is in treatment group.



Welz, ten Haaf, Alfons CITRUS October 21, 2021 9 / 13

### Setup

The DGP for potential outcomes can w.l.o.g. be viewed as

$$Y_i(W_i) = g_i \left(\theta(\mathbf{X}_i)W_i + \nu(\mathbf{X}_i) + \varepsilon_i\right).$$

- $g_i : \mathbb{R} \to \{0,1\}$  maps to binary outcome space;
- $\theta(X_i)$  is the HTE function: causal effect of  $W_i$  on  $Y_i$ ;
- $\nu(\mathbf{X}_i)$  is the nuisance function: raw effect of  $\mathbf{X}_i$  on  $Y_i$ ;
- $\varepsilon_i$  is zero-mean noise term.



Welz, ten Haaf, Alfons CITRUS October 21, 2021 10 / 13

#### Outline

Introduction

2 Data Generation: Considered Scenarios

3 Estimation: Considered Methods



Welz, ten Haaf, Alfons CITRUS October 21, 2021 11/13



Bias In Medicine: Last Week Tonight with John Oliver (HBO)

8,058,422 views • Aug 19, 2019

△ 142K 

√ 15K 

⇒ SHARE 

=+ SAVE

4□ > 4ⓓ > 4≧ > 4≧ > ½
900

Welz, ten Haaf, Alfons CITRUS October 21, 2021

#### References

Sackett, D. L., Rosenberg, W. M., Gray, J. M., Haynes, R. B., and Richardson, W. S. (1996). Evidence-Based Medicine: What it is and What it isn't. The British Medical Journal, 312(7023):71-72.